Early trial aims to halt return of aggressive brain tumors
NCT ID NCT06410248
Summary
This early-stage study is testing a new drug combination for adults whose aggressive brain cancer (glioblastoma) has returned. Researchers want to find the safest and most effective dose of an experimental drug called triapine when given with the standard chemotherapy temozolomide. The main goal is to see if this combination can help control tumor growth and extend life for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA IDH WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.